Kimia Biosciences logo

Kimia Biosciences financials: balance sheet, profit and loss, cash flow

BSE: 530313Pharmaceuticals & BiotechnologySmall Cap

KIMIA BIOSCIENCES LIMITED · Face value ₹1 · Listed May 1995
Last close ₹30.82₹0.00 (0.00%)

Share price at the BSE close on 27 Oct 2026. Previous close ₹30.82.

27 Oct: open ₹30.97, high ₹30.97, low ₹30.07

52-week range of traded prices to 27 Oct 2026
₹23.20Low, 30 Mar 2026₹43.28High, 16 Feb 2026
Market cap
₹146 Cr2,580th largest listed
P/E
20.29
P/B
8.23
Dividend yield
Nonein the last 12 months
ROE
51.9%
ROCE
19.1%
Debt to equity
1.95
Volume, BSE
416

Kimia Biosciences' financial statements for the 10 years to Mar 2026, standalone: the listed company alone, without its subsidiaries, with the twelve months to Jun 2026 after them.

10 years at a glance

₹ crore, years to March.Kimia Biosciences annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
  • Loss
1.5−0.9Mar 17594.1Mar 18943.930Mar 191061.431Mar 201335.141Mar 21125−3.741Mar 22129−9.453Mar 23105−5.343Mar 241199.633Mar 251157.435Mar 26
Peak revenue ₹133 Cr, year to Mar 2021; lowest ₹1.46 Cr, year to Mar 2017A loss in 4 of the 10 years shown

Operating and net margin, per cent

  • Operating margin
  • Net margin
17.0%−68.5%−68.5%7.8%5.9%4.2%6.3%0.5%−3.9%−0.5%17.0%12.4%−65.0%6.9%4.1%1.3%3.8%−3.0%−7.3%−5.1%8.1%6.5%Mar 17Mar 19Mar 21Mar 23Mar 25Mar 26

From Apr 2019 leases sit on the balance sheet: rent is charged as depreciation and interest instead, so operating profit and total assets step up with nothing about the business having changed. Borrowings here leave lease liabilities out. Lease payments were 72.7% of operating profit in the first full year.

Results for the year to Mar 2026

Standalone: the listed company alone, without its subsidiaries. ₹ crore.

From revenue to net profit

  1. Revenue115
  2. Materials and goods−70
  3. Employee costs−13
  4. Other expenses−18
  5. Operating profit14
  6. Depreciation−3.9
  7. Other income+1.6
  8. One-off items0.0
  9. Finance costs−3.5
  10. Profit before tax8.5
  11. Tax−1.0
  12. Net profit7.4

What the company owns

  • Plant, investments and other assets₹47 Cr
  • Receivables₹29 Cr
  • Inventory₹26 Cr
  • Cash and bank₹1 Cr

What pays for it: net worth and liabilities

  • Owed to suppliers₹42 Cr
  • Borrowings₹35 Cr
  • Net worth₹18 Cr
  • Other liabilities₹9 Cr

Profit and loss

Standalone, ₹ crore, years to March. The last column is the twelve months to Jun 2026, the latest four quarters added.Kimia Biosciences quarterly results

₹ croreMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 29 MayJun 2026Twelve monthsFiled 10 Aug
Revenue from operations15994106133125129105119115112
254881021241241331059910198
Materials and goods bought–46718097929675717067
Employee costs–491114151615141312
Other expenses–581113172115141818
Operating profit before depreciation−156481−50201414
Operating margin−68.5%7.8%5.9%4.2%6.3%0.5%−3.9%−0.5%17.0%12.4%12.6%
Materials, % of revenue–77.3%75.7%75.5%73.0%73.9%74.7%71.8%59.6%61.0%60.0%
Employee costs, % of revenue–7.2%9.4%10.2%10.6%12.1%12.8%14.4%11.5%11.0%11.0%
Other expenses, % of revenue–7.7%9.0%10.1%10.1%13.6%16.4%14.3%11.9%15.6%16.5%
Depreciation and amortisation01122333344
Operating profit after depreciation−14436−2−8−4171010
Other income10112112121
Finance costs00233445543
Profit before one-off items and tax−14416−5−11−71488
One-off items––0000−10000
Profit before tax−14416−5−12−71488
0–000−1−3−2411
Net profit−14415−4−9−51077
Other comprehensive income––000000000
Total comprehensive income––415−4−9−51088
Net margin−65.0%6.9%4.1%1.3%3.8%−3.0%−7.3%−5.1%8.1%6.5%6.4%
Materials, employee costs and other expenses are shown for the years they add up to operating expenses; for the year to Mar 2017 they do not, so they are left blank.

Balance sheet

Standalone, ₹ crore, at 31 March.

₹ croreMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 29 May
6131815501018
Share capital25555555
Reserves4914101−4513
3031414153433335
3039516276698261
2934373339301924
6586107109121100111103
1825353639393640
4861707383617564
Net debt2829404052433234
Borrowings are counted again inside the liabilities due within a year and after a year. No balance sheet is on record for the years to Mar 2017 and Mar 2018, so its lines and the ratios worked from it are blank there.

Cash flow

Standalone, ₹ crore, years to March.

₹ croreMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 29 May
6.08.1−6.814.521.310.8
5.98.1−6.315.020.510.9
−3.27.1−2.013.9–−4.8
Receivables−5.39.31.13.9–2.9
Inventories−3.4−13.3−11.217.4–8.3
Payables5.511.28.1−7.4–−15.8
Other working capital0.00.00.00.0–−0.3
Tax paid0.0−0.10.00.00.0−0.1
Interest paid0.00.00.00.00.00.0
Capital spending13.63.62.81.54.68.2
Free cash flow−7.64.5−9.613.016.72.7
−13.6−0.7−2.8−1.5−4.7−8.1
8.0−7.79.5−13.1−16.6−2.6
Dividends paid0.00.00.00.00.00.0
Shares bought back0.00.00.00.00.00.0
Shares issued0.00.00.00.00.00.0
Net change in cash0.4−0.30.00.00.00.1
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only. No cash flow statement is on record for the years to Mar 2017, Mar 2018, Mar 2019 and Mar 2020.

Per share

Standalone, ₹ per share, years to March.

₹ per shareMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 29 May
Earnings per share−₹0.13₹5.49₹2.64₹0.32₹1.08−₹0.78−₹1.98−₹1.12₹2.03₹1.64
Diluted earnings per share−₹0.13₹5.49₹1.39₹0.28₹1.08−₹0.78−₹1.98−₹1.12₹2.03₹1.64
Book value per share––₹4.18₹2.88₹3.90₹3.15₹1.15₹0.07₹2.11₹3.75
Shareholder yield––––0.0%0.0%0.0%0.0%0.0%0.0%
Market cap at the year end (₹ crore)16385293180178154264201111

Ratios

Standalone, years to March.Kimia Biosciences PE ratio and valuation

RatioMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 29 May
Revenue growth660.4%3,931.9%59.5%13.2%24.9%−5.9%2.9%−18.4%13.4%−3.4%
Operating profit growth––20.7%−20.1%88.2%−92.5%–––−29.5%
Net profit growth––−5.0%−64.2%269.6%––––−22.7%
Earnings per share growth––−51.9%−87.9%237.5%––––−19.2%
––63.1%14.2%32.1%−22.2%−91.9%−183.3%186.7%53.7%
–––−48.9 pts17.9 pts−54.3 pts−69.7 pts−91.3 pts370.0 pts−133.0 pts
From the net margin–––−43.1 pts27.8 pts−56.8 pts−32.3 pts28.0 pts475.9 pts−37.2 pts
From asset turnover–––−0.4 pts−0.8 pts4.0 pts2.0 pts9.5 pts55.1 pts−7.2 pts
From borrowing–––−5.4 pts−9.1 pts−1.5 pts−39.3 pts−128.8 pts−161.0 pts−88.5 pts
Return on capital employed––12.6%6.3%10.8%−4.2%−14.2%−8.6%39.7%19.8%
Cash conversion––––116.9%–––221.2%145.9%
Interest cover–20.32.21.11.9–––3.72.9
Debt to equity––4.842.292.252.739.69131.123.271.95
Receivable days––11312811588879611393
Inventory days––839289146183149178137
Payable days––91121116171177194260220
Cash conversion cycle, days––105100886393513110
Working capital days––8394847879474643
Asset turnover––1.441.411.381.161.110.951.131.07
Assets per rupee of net worth––10.717.766.056.4911.3438.1920.517.74
Sales per rupee of plant––5.876.404.693.563.833.333.853.82
Capital spending to depreciation––––7.101.220.840.461.362.09
Plant being built, % of plant in use––9.5%34.6%20.4%0.0%1.8%1.8%0.0%–
Interest cover is left blank for the years to Mar 2017, Mar 2022, Mar 2023 and Mar 2024: operating profit after depreciation is a loss, and a loss covers no interest bill. No balance sheet is on record for the years to Mar 2017 and Mar 2018, so its lines and the ratios worked from it are blank there.

Growth and returns over 3, 5 and 10 years

Standalone: the listed company alone, without its subsidiaries. Each window ends with the year to Mar 2026.

Return on assets, latest year
6.9%
Cash from operations against operating profit
76.0%
Measure10 years5 years3 years
Revenue growth, yearly rate89.5%−2.8%−3.7%
Profit growth, yearly rate–7.8%–
Return on equity, average–−11.4%19.0%
Return on capital employed, average–6.5%16.9%
Operating margin, average−1.9%5.1%9.7%
Net margin, average−5.0%−0.2%3.2%
Asset turnover, average–1.081.05
Cash conversion cycle, days, average–5031
Interest cover, average––3.3
Debt to equity, average–29.7545.45

Where the cash came from and went

Standalone: the listed company alone, without its subsidiaries. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ crore5 years3 yearsLatest year
Cash from operations47.946.610.8
Cash from investing−17.8−14.3−8.1
Cash from financing−30.4−32.3−2.6
Capital spending20.714.38.2
Dividends paid0.00.00.0
Shares bought back0.00.00.0
Shares issued for cash0.00.00.0
Borrowings raised44.912.15.4
Borrowings repaid59.134.27.0

Accounting checks

Standalone, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Piotroski score, out of 9Published threshold 3 points out of 9––643695
Altman Z-scorePublished threshold 1.812.652.613.142.481.712.412.802.48
Beneish M-scorePublished threshold −1.78––−2.49−3.66−1.67−3.27−2.94−2.39
Profit not backed by cash, % of assetsPublished threshold 10 per cent of average total assets––13.25−10.230.19−16.59−6.584.37
Cash from operations to profit, 3 yearsPublished threshold 0.7 times–––––––3.97
Receivables growth less revenue growthOur threshold 0 percentage points–15.00−12.97−21.80−1.618.4719.99−16.82
Inventory growth less cost-of-goods growthOur threshold 0 percentage points–13.27−4.0861.0226.21−14.5018.10−23.02
Other current assets growth less revenue growthOur threshold 5 per cent of revenue–1.000.631.86−1.49−1.791.513.43
Assets under construction, years of additionsOur threshold 2 years of additions–2.530.430.000.340.460.00–
Effective tax ratePublished threshold 17.16 per cent−1.30−12.657.77–––29.5012.13
Tax charged less tax paid, % of profitOur threshold 10 percentage points––––––29.5011.32
A threshold marked as ours has no published figure; it is the line we read the check against.